| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PLoSO...750763K |
| P356 | DOI | 10.1371/JOURNAL.PONE.0050763 |
| P932 | PMC publication ID | 3511312 |
| P698 | PubMed publication ID | 23226377 |
| P5875 | ResearchGate publication ID | 233888987 |
| P2093 | author name string | Dione T Kobayashi | |
| Karen S Chen | |||
| Nabil Ghazal | |||
| Phillip Zaworski | |||
| Laurel Sly | |||
| Brett Chung | |||
| Douglas Decker | |||
| James Vanderlugt | |||
| Julie McGonigal | |||
| Karen Klott | |||
| P2860 | cites work | DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies. | Q53799252 |
| Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid | Q60361416 | ||
| Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC | Q64377277 | ||
| Comparison of cytokine production in blood cell cultures of healthy children and adults | Q71375846 | ||
| In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate | Q83139606 | ||
| Survival probabilities of patients with childhood spinal muscle atrophy | Q83422469 | ||
| Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society | Q37799656 | ||
| Biomarkers in rare disorders: the experience with spinal muscular atrophy | Q37845667 | ||
| Spinal muscular atrophy: a clinical and research update | Q37971125 | ||
| A generalizable pre-clinical research approach for orphan disease therapy | Q38019219 | ||
| A sensitive assay for measuring SMN mRNA levels in peripheral blood and in muscle samples of patients affected with spinal muscular atrophy | Q38300319 | ||
| A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. | Q39960453 | ||
| SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials | Q40315627 | ||
| Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. | Q40480552 | ||
| Valproic acid increases SMN levels in spinal muscular atrophy patient cells. | Q40620622 | ||
| Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA | Q40882876 | ||
| Correlation between severity and SMN protein level in spinal muscular atrophy | Q41102726 | ||
| RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN | Q41275236 | ||
| Time-dependent changes in the expression of lymphocyte and monocyte cell adhesion molecules after meals of different composition | Q42475429 | ||
| The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. | Q42485526 | ||
| Spinal muscular atrophy: survival pattern and functional status | Q43315814 | ||
| Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice | Q45865368 | ||
| Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation | Q47399907 | ||
| SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR | Q24599124 | ||
| Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism | Q24613087 | ||
| Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy | Q24647245 | ||
| Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells | Q28252944 | ||
| The changing natural history of spinal muscular atrophy type 1 | Q28257091 | ||
| Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients | Q28291453 | ||
| Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design | Q28293151 | ||
| Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. | Q28378727 | ||
| Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study | Q28730280 | ||
| Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study | Q28730283 | ||
| Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses | Q28740896 | ||
| Consensus Statement for Standard of Care in Spinal Muscular Atrophy | Q29028573 | ||
| Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy | Q30492560 | ||
| CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy | Q30493891 | ||
| A novel cell immunoassay to measure survival of motor neurons protein in blood cells | Q33232855 | ||
| VACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples | Q33244711 | ||
| Treatment of spinal muscular atrophy by sodium butyrate | Q33933841 | ||
| Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. | Q33997498 | ||
| Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model | Q34030144 | ||
| Collection and processing of whole blood for transformation of peripheral blood mononuclear cells and extraction of DNA: the Type 1 Diabetes Genetics Consortium | Q34051595 | ||
| Gene Expression Profiles from Peripheral Blood Mononuclear Cells Are Sensitive to Short Processing Delays | Q34199302 | ||
| Progress and promise: the current status of spinal muscular atrophy therapeutics. | Q34227846 | ||
| A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse | Q34241874 | ||
| Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy | Q34353103 | ||
| Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy | Q34616822 | ||
| Natural history of denervation in SMA: relation to age, SMN2 copy number, and function | Q35101830 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e50763 | |
| P577 | publication date | 2012-11-30 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein | |
| P478 | volume | 7 |
| Q36205773 | A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls |
| Q34082155 | Assays for the identification and prioritization of drug candidates for spinal muscular atrophy |
| Q36565221 | Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. |
| Q35808086 | Biomarker for Spinal Muscular Atrophy: Expression of SMN in Peripheral Blood of SMA Patients and Healthy Controls |
| Q34658131 | SMA-MAP: a plasma protein panel for spinal muscular atrophy |
| Q35949008 | SMN Protein Can Be Reliably Measured in Whole Blood with an Electrochemiluminescence (ECL) Immunoassay: Implications for Clinical Trials |
| Q42638317 | Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy. |
Search more.